Jeanne Marrazzo, MD
Enriched profileChief Executive Officer, Infectious Diseases Society of America (IDSA) · Infectious Diseases Society of America (IDSA)
Jeanne Marrazzo is Chief Executive Officer, Infectious Diseases Society of America (IDSA) at Infectious Diseases Society of America (IDSA). OpenAlex indexes 399 publications with 16,973 citations (h-index 61); ClinicalTrials.gov lists 3 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 10% of Infectious Disease profiles in the findmyKOL directory.
Data verified 23 Oct 2026
Overview
Updated 25 Oct 2026
Jeanne Marrazzo is Chief Executive Officer, Infectious Diseases Society of America (IDSA). The public record shows 399 publications with 16,973 citations (h-index 61), centered on Reproductive tract infections research, HIV/AIDS Research and Interventions, Cervical Cancer and HPV Research. It also documents an investigator role on 3 registered clinical trials, industry payments reported by 4 companies, 6 NIH-funded awards (2016–2023).
- Most recent indexed publication: 2026 · Journal of virology
- Top research focus: Reproductive tract infections research
- 3 registered trials on ClinicalTrials.gov
- Open Payments reporting from 4 companies
Generated from the cited public record · current as of 25 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 6 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 175.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 25 Oct 2026
Listed as an investigator on 3 registered studies on ClinicalTrials.gov. The most recent:
- Effects of Contraceptive Ring on Vaginal Microbiota, HIV Shedding and Local Immunity
Sponsor: University of Washington
- Safety and Effectiveness of TFV 1% Gel, TDF Tablets, and FTC/TDF Tablets in Preventing HIV in Women
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
- Vancomycin Or Trimethoprim/Sulfamethoxazole for Methicillin-resistant Staphylococcus Aureus Osteomyelitis
Sponsor: University of Washington
Industry payments
Updated 25 Oct 2026
4 companies reported payments to CMS in program years 2021–2023. These are public disclosures, not judgments. The latest:
- Gilead Sciences, Inc.Program year20232 payments
- Merck Sharp & Dohme LLCProgram year20222 payments
- Gilead Sciences, Inc.Program year20221 payment
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
100%Glycopeptide Antibacterial43.6%Vancomycin Hcl100%Part D<11 patientsLipopeptide Antibacterial28.2%Daptomycin100%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 25 Oct 2026
6 NIH research awards on record, funded 2016–2023 per NIH RePORTER. The latest:
- Sexually Transmitted Infections Clinical Trials Group: Phase 2 Clinical Trial to Evaluate a Vaccine Candidate for Neisseria Gonorrhoeae
University of Alabama at Birmingham
FY2022$3,074,366272201300012I
Publications
Updated 25 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Navigating the path forward for evidence-based management of long COVID.
Nature immunology
Article2025 - Diverse Metrics of Success for Physician-Scientists: Reflections on My Path and the Evolving Role of the National Institute of Allergy and Infectious Diseases.
The Journal of infectious diseases
Article2025
Most-cited works
by citation count (OpenAlex)- 01Molecular Identification of Bacteria Associated with Bacterial VaginosisArticle1,302 citations2005
- 02Tenofovir-Based Preexposure Prophylaxis for HIV Infection among African WomenArticle1,297 citations2015
- 03Cabotegravir for HIV Prevention in Cisgender Men and Transgender WomenArticle904 citations2021
- 04Development of a Definition of Postacute Sequelae of SARS-CoV-2 InfectionArticle848 citations2023
- 05Sexually transmitted infections: challenges aheadArticle755 citations2017
Network
Updated 25 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 25 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/jeanne-marrazzo-md
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 25 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- MD
MPH
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →hivma.org ↗
Editorial & leadership roles
journal and society appointments- Director
National Institute of Allergy and Infectious Diseases (NIAID), most recent government post before IDSA
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →hivma.org ↗ - Director
Division of Infectious Diseases, University of Alabama at Birmingham (former; C. Glenn Cobbs Endowed Chair in Infectious Diseases)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →hivma.org ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →treatmentactiongroup.org ↗
- Elected member
National Academy of Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →niaid.nih.gov ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Baha Sibai, MD
McGovern Medical School at UTHealth Houston
Robert Coleman, MD
Vaniam Group
Kathleen Moore, MD
University of Nebraska Medical Center
Bradley Monk, MD
Florida Cancer Specialists & Research Institute